Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

Abstract

Seventeen patients with malignant mesothelioma were treated in a phase II study with carboplatin, a cisplatin analogue without significant nephrotoxicity or neurotoxicity. The drug was given in a dose of 300–400 mg/m2 by i.v. infusion, repeating at 28-day intervals. One patient achieved a complete clinical and radiological remission of 15 months' duration… (More)
DOI: 10.1007/BF00273404

Topics

  • Presentations referencing similar topics